BridgeBio Pharma Stock

BridgeBio Pharma EBIT

The EBIT of BridgeBio Pharma (BBIO) as of Aug 16, 2026 is -576.60 M USD. In the previous year, EBIT was -592.97 M USD — a change of -2.76% (higher).

EBIT

-576.60 MUSD

YoY

-2.76%

Last updated:

In 2026, BridgeBio Pharma's EBIT was -576.60 M USD, a -2.76% increase from the -592.97 M USD EBIT recorded in the previous year.

The BridgeBio Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
Jan 1, 2030 (e)
0.00 base
YEAREBIT (undefined USD)
2030 est -
2029 est -
2028 est -
2027 est -
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
Access this data via the Eulerpool API

BridgeBio Pharma Revenue

BridgeBio Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
9.30 M USD
-590.00 M USD
-643.20 M USD
Jan 1, 2024
221.90 M USD
-592.97 M USD
-535.76 M USD
Jan 1, 2025
502.08 M USD
-576.60 M USD
-729.31 M USD
Jan 1, 2026 (e)
960.73 M USD
-961.37 M USD
-421.78 M USD
Jan 1, 2027 (e)
1.61 B USD
-1.60 B USD
111.81 M USD
Jan 1, 2028 (e)
2.46 B USD
-2.46 B USD
731.74 M USD
Jan 1, 2029 (e)
3.57 B USD
-3.57 B USD
1.50 B USD
Jan 1, 2030 (e)
4.50 B USD
-4.50 B USD
2.01 B USD

BridgeBio Pharma Margins

BridgeBio Pharma stock margins

The BridgeBio Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BridgeBio Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BridgeBio Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
73.71 %
-6,342.04 %
-6,913.92 %
Jan 1, 2024
98.25 %
-267.22 %
-241.44 %
Jan 1, 2025
94.37 %
-114.84 %
-145.26 %
Jan 1, 2026 (e)
94.37 %
-100.07 %
-43.90 %
Jan 1, 2027 (e)
94.37 %
-99.31 %
6.94 %
Jan 1, 2028 (e)
94.37 %
-100.00 %
29.69 %
Jan 1, 2029 (e)
94.37 %
-100.00 %
42.13 %
Jan 1, 2030 (e)
94.37 %
-100.00 %
44.54 %

BridgeBio Pharma Stock analysis

What does BridgeBio Pharma do? BridgeBio Pharma Inc. is a US biotech company founded in 2015. The company is based in Palo Alto, California and specializes in researching and developing medications for rare diseases. BridgeBio's business model is based on a pipeline of rare diseases that have little or no existing treatment options. The company identifies, finances, and operates individual independent subsidiary companies with the goal of developing precision medicines for rare and genetic diseases. An important element of BridgeBio's business strategy is strategic collaboration with academic institutions and other companies to share research and development expertise. BridgeBio has various subsidiary companies, each specializing in the development of medications for a specific genetic disease. These include Eidos Therapeutics, QED Therapeutics, PellePharm, Navire Pharma, Origin Biosciences, CoA Therapeutics, Calcilytix Therapeutics, Phoenix Tissue Repair, and MyoKardia. Eidos Therapeutics is constantly searching for therapies for transthyretin-mediated amyloidosis (ATTR), a rare cardiovascular disease caused by the buildup of amyloid proteins in various parts of the body. The first FDA-approved eprodisate therapy became available in Japan in 2005, making Eidos Therapeutics one of the most promising subsidiary companies of BridgeBio. QED Therapeutics specializes in developing therapies for Gorlin syndrome and medulloblastoma, a type of brain tumor. PellePharm aims to develop a topical therapy for Gorlin syndrome that can be used to control and treat tumors and non-tumorous skin changes. Navire Pharma explores specific kinases that influence cell growth and cell death signaling pathways to identify healing methods for cancer patients. Calcilytix Therapeutics focuses on discovering a treatment solution for chronic kidney diseases, with a main focus on stopping or reducing the loss of kidney function. Overall, BridgeBio is dedicated to the development of precision medicines designed to combat the underlying genetic causes of rare diseases. The company also advances the field of precision medicine and works closely with doctors and patients to improve the diagnosis of rare diseases and optimize patient care. In 2019, BridgeBio Pharma announced a strategic partnership with the Pharmaceutical Research and Manufacturers of America (PhRMA). The goal of this collaboration is to improve awareness of rare diseases and create better access to new medications. BridgeBio hopes that the partnership will accelerate the development of therapies for rare diseases. In conclusion, BridgeBio Pharma Inc. is an innovative biotech company specializing in the development of precision medicines for the treatment of rare genetic diseases. With a business model based on collaboration with subsidiary companies and strategic partners, BridgeBio Pharma Inc. aims to revolutionize the treatment and cure of patients with rare genetic diseases. BridgeBio Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BridgeBio Pharma's EBIT

BridgeBio Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BridgeBio Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BridgeBio Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BridgeBio Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BridgeBio Pharma stock

EBIT of BridgeBio Pharma is -576.60 M USD in 2026.

EBIT of BridgeBio Pharma changed from -592.97 M USD to -576.60 M USD, representing a -2.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT BridgeBio Pharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's BridgeBio Pharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — BridgeBio Pharma

All Key Metrics — BridgeBio Pharma